Startup Altido Therapeutics is trying to commercialize CAR-T cell therapy to treat glioblastoma, which is almost always fatal. Glioblastoma is a highly aggressive brain tumor with a poor prognosis and few effective treatment options. CAR-T therapy uses the patient's own T-cells, which are genetically modified to recognize and destroy tumor cells. The studies showed rapid tumor regression in the first three patients without serious adverse events. In some clinical trials, 50% of patients (29 of 58) achieved stable disease or better, including two partial responses and one complete response. One optimized group experienced survival longer than 12 months in 43% of patients (9 of 21) with a median overall survival of 10.2 months. CAR-T cells have been administered in a safe manner both peripherally and locoregionally, but with variable clinical efficacy. These results suggest the promise of CAR-T therapy for glioblastoma despite challenges such as antigen loss and the tumor's immunosuppressive environment.